Abstract 1302P
Background
Differences in biological sex and gender may have impact on treatment allocation and survival in patients with localized and locally advanced pancreatic cancer. The aim of the present study is to systematically analyse patient- and tumour characteristics, treatment allocation and overall survival in patients with stage I-III pancreatic cancer in the Netherlands.
Methods
In this nationwide, multicentre cohort study patients with non-metastatic pancreatic cancer diagnosed between 2015 and 2020 were selected from the Netherlands Cancer Registry. The association between gender and the probability of receiving surgical treatment or systemic chemotherapy were examined with multivariable logistic regression analyses. Overall survival was assessed by Kaplan Meier method with log rank test and multivariable Cox proportional hazard analysis.
Results
Out of 6855 patients with stage I-III pancreatic cancer, 3344 (48.8%) were men. More men were younger than 70 years compared to women (41% vs. 35%, p=<.001) and men more often had ≥2 comorbidities (26% vs. 20%, p=<.001). Multivariable logistic regression analyses with adjustment for confounders (age, performance status, comorbidities, tumor location, tumor stage and previous malignancies) showed that women less often received surgical treatment and systemic chemotherapy compared to men (OR 0.855, 95% CI 0.759-0.964, p=0.010 and OR 0.761, 95% CI 0.672-0.862, p=<.001 respectively). Furthermore, women had worse overall survival compared to men (median OS 8.4 and 9.1 months respectively, p=0.01). After adjustment for cofnounders (age, performance status, comorbidities, tumor location, tumor stadium and previous malignancies) no sifnificant survival difference remained (HR[women vs men] 0.980, CI 0.966-1.078, p=0.479). In patients who received cancer treatment, no significant survival differences were found between men and women, both in univariable and multivariable analyses.
Conclusions
This study found that men significantly more often received surgical treatment or chemotherapy. No significant difference was found in overall survival between men and women after adjustment for confounders.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.